Skip to main content
Premium Trial:

Request an Annual Quote

Proteome and Egenix to Develop Semen-Screening Diagnostic for Prostate Cancer

NEW YORK, March 7 (GenomeWeb News) - Proteome and Egenix will co-develop a semen-based diagnostic kit for prostate cancer, Proteome said today.


The non-invasive test will be based on the human carcinoma antigen.


Under the agreement, Egenix will fund research to optimize the detection of HCA in semen of prostate cancer patients. The companies will then share the rights for further development and commercialization of the test.


Egenix estimated a potential US market size for the HCA test of up to $1.5 billion, according to a statement.


"We initially wondered if there would be social or cultural objections to a test that requires the patient to provide an ejaculate specimen," said Egenix president Jedd Levine. "But it's common to look in organ secretions for signs of cancer in that organ and ... most men would willingly provide a semen specimen to potentially avoid a painful needle biopsy."

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.